Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity

By Steve Jenkinson, VP Drug Discovery and Safety Assessment, Metrion Biosciences

Currently, only 10% of the drugs that enter Phase I receive marketing approval from the U.S. Food and Drug Administration (FDA), with unmanageable toxicity accounting for approximately 30% of the clinical failures for investigational new drugs (INDs). Safety-based discontinuation of INDs is mainly associated with cardiotoxicity (which is also one of the most common reasons for the withdrawal of marketed drugs).

The discontinuation and/or withdrawal of some of these drugs could have been predicted preclinically with more thorough safety screening, including validated Good Laboratory Practice (GLP) in vitro screening assays.

By performing GLP-compliant hERG assays, companies can speed the development of cardiovascular drugs by potentially replacing the need to run thorough QT studies.

Read the full article: Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50.

Find out about our GLP hERG screening services.

Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram